The GVAX vaccine was administered in locally advanced, unresectable, or metastatic PDA patients in combination with ipilimumab (targeting CTLA-4 (NCT00836407) or nivolumab (targeting PD-1) as well as CRS-207 (NCT02243371). Here, CTLA4 is linked to Patent ductus arteriosus.